All data are based on the daily closing price as of June 6, 2025
t
Torii Pharmaceutical
4551.TSE
43.99 USD
-0.22
-0.50%
Overview
Last close
43.99 usd
Market cap
1.24B usd
52 week high
44.40 usd
52 week low
21.80 usd
Target price
29 usd
Valuation
P/E
32.051
Forward P/E
N/A
Price/Sales
2.8905
Price/Book Value
1.4705
Enterprise Value
934.52M usd
EV/Revenue
2.1953
EV/EBITDA
18.2322
Key financials
Revenue TTM
425.70M usd
Gross Profit TTM
173.14M usd
EBITDA TTM
51.88M usd
Earnings per Share
1.37 usd
Dividend
N/A usd
Total assets
916.82M usd
Net debt
-21.52M usd
About
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents for renal diseases and hemodialysis, such as ENAROY tablets to treat anemia associated with CKD; Riona tablets for the treatment of hyperphosphatemia/iron deficiency anemia (IDA); and REMITCH, an oral therapeutic agent for the treatment of pruritus. The company provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; VTAMA cream, a topical treatment for atopic dermatitis and plaque psoriasis; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. It markets its products primarily through medical representatives for medical professionals. The company has a collaboration with ALK-Abelló A/S to develop and commercializes ALK's allergen immunotherapy drug targeting pollen diseases caused by grass pollen. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.